Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018

Executive Summary

Despite an expected absence of large floats like that of Celltrion Healthcare last year, IPOs by biotech and pharma firms in South Korea are poised to rise in 2018 amid an improved stock listing environment and progress in novel drug development.

Advertisement

Related Content

OliX Eyes RNAi Leadership In Asia And Beyond
AbClon Shines On Korean Debut Amid Robust Investor Interest
Spotlight On TissueGene’s Upcoming Korea IPO
Interview: Fledgling ABL Bio And Its Global Ambitions In Bispecific Antibodies
Celltrion Healthcare IPO To Accelerate Celltrion's Global Biosimilar Expansion
Interview: OliPass An Oligonucleotide Outsider With Big Ambitions
After Record Series A, Eutilex Eyes T-Cell, Antibody Partnerships
Promising Tanibirumab Trial Boosts PharmAbcine’s Confidence
INTERVIEW: Bridge Chief On Pursuing NRDO, Global Ambitions
SK Bio To Go All The Way With Novel Epilepsy Drug

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100347

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel